Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

251
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
251
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

212
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
212
Brain Imaging01:14

Brain Imaging

629
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
629
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

460
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
460
Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

758
Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
758

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

阿尔茨海默氏症成像联盟

Simone P Zehntner1, Jean-Philippe Coutu1, Felix Carbonell1

  • 1Biospective Inc., Montreal, QC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括
此摘要是机器生成的。

先进的MRI技术精确地跟踪皮层基底退化 (CBD) 的进展,并将其与其他疾病区分开来. 这通过减少样本大小要求来加速罕见神经退行性疾病的临床试验.

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

相关实验视频

Last Updated: Jan 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.0K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

40.8K

科学领域:

  • 神经成像是一种神经成像.
  • 神经学 神经学
  • 生物标志物 生物标志物

背景情况:

  • 皮层骨干退化 (CBD) 是一种罕见的神经退行性疾病,其特征是蛋白积累和神经元损失.
  • CBD与其他帕金森综合征具有相同的临床症状,这给诊断带来了挑战.
  • 包括体积和扩散MRI (dMRI) 在内的MRI生物标志物对于监测疾病进展和改善临床试验至关重要.

研究的目的:

  • 使用先进的成像技术探索CBD的进展.
  • 为了区分CBD与类似的神经退行性疾病,如渐进性超核麻 (PSP).
  • 评估MRI生物标志物的有用性,以减少临床试验的样本大小要求.

主要方法:

  • 利用CBD,PSP和4RTNI和FTLDNI研究中的健康对照队伍的MRI数据.
  • 使用PIANOTM软件平台进行灰色物质密度和区域体积分析.
  • 分析了dMRI指标,包括辐射扩散率 (RD) 和自由水 (FW),以检测微观结构变化.
  • 进行了样本大小计算,以确定临床试验所需的参与者数量.

主要成果:

  • 在12个月的时间里,CBD受试者表现出快速的大脑缩,感觉运动皮层,皮层和皮层的灰质密度显著下降.
  • 体积测量分析显示2.5%-5%的区域减小和和海马体的皮下缩.
  • 在12个月的时间里,dMRI显示白质和皮质区域的区域平均扩散率在12个月内变化高达5%.
  • 与FreeSurfer相比,PIANOTM平台显著降低了样本大小要求,需要30-44名受试者进行临床试验.

结论:

  • 先进的MRI,结合体积和扩散分析,准确地跟踪CBD的进展,并将其与PSP区分开来.
  • 这种方法可以通过最小化样本大小并使早期治疗评估成为可能,从而加速对罕见神经退行性疾病的临床试验.
  • 整合强大的成像生物标志物对于改善CBD等疾病的诊断准确性和治疗干预至关重要.